Hellerup: A new achondroplasia treatment moved closer to the European market after the European Medicines Agency’s human medicines committee recommended Yuviwel, with the active substance navepegritide, for children. The Committee for Medicinal Products for Human Use backed the product at its 12 to 15 October 2026 meeting, and the agency published the highlights on 16 October.
Achondroplasia is an inherited condition caused by a mutation in the gene for fibroblast growth-factor receptor 3. The mutation affects the growth of most bones and causes very short stature. Ascendis Pharma Growth Disorders A/S is the applicant for this achondroplasia treatment, and the medicine carries orphan designation, the status the EU grants to treatments for rare conditions.
The opinion is only a recommendation. The European Commission takes the legally binding decision on a marketing authorisation, and that decision is still pending. In normal practice the Commission acts within about two months of a committee opinion, which would bring a possible authorisation into the new year. A positive decision would make the achondroplasia treatment available under a single authorisation valid across all EU Member States. The committee reaches its opinions after a scientific evaluation of quality, safety and efficacy, and the agency publishes a public assessment report once the Commission has decided.
Yuviwel was one of six new medicines recommended in October, alongside five extensions of indication, and it was the only one aimed at a skeletal growth disorder. The committee also endorsed two biosimilars, Fovlussea, a ranibizumab product for wet age-related macular degeneration and several other retinal conditions, and Neuzafy, a filgrastim product for neutropenia. A hybrid application, Kizfizo, containing temozolomide, was recommended for glioblastoma multiforme in adults and malignant glioma in children.
Not every file ended in approval. The committee confirmed its refusal of marketing authorisation for Yartemlea, narsoplimab, after a re-examination. Omeros Ireland had sought the product for thrombotic microangiopathy associated with haematopoietic stem cell transplantation in patients from two years of age. Two extension applications, for Ibrance and Truqap, were withdrawn, and the committee did not recommend extending Mylotarg to children with newly diagnosed acute myeloid leukaemia.
The year-to-date statistics show how busy the committee has been. It has issued 72 positive opinions on new medicines in 2026 and eight negative ones, together with 97 positive opinions on extensions of indication. For families waiting on an achondroplasia treatment, the next milestone is the Commission decision, after which national pricing and reimbursement talks begin in each Member State, and patients will only see the achondroplasia treatment once those talks conclude.
